Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
LY9 belongs to the SLAM family of immunomodulatory receptors (see SLAMF1\; MIM 603492) and interacts with the adaptor molecule SAP (SH2D1A\; MIM 300490) (Graham et al., 2006 [PubMed 16365421]).[supplied by OMIM, Mar 2008].. Zusätzlich bieten wir Ihnen LY9 Proteine (16) und LY9 Kits (8) und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 136 products:
Mouse (Murine) Monoclonal LY9 Primary Antibody für FACS, IF - ABIN2660997
Graham, Bell, McCausland, Huntoon, van Deursen, Faubion, Crotty, McKean: Ly9 (CD229)-deficient mice exhibit T cell defects yet do not share several phenotypic characteristics associated with SLAM- and SAP-deficient mice. in Journal of immunology (Baltimore, Md. : 1950) 2005
Zeige alle 5 Referenzen für 2660997
Mouse (Murine) Monoclonal LY9 Primary Antibody für FACS - ABIN2663193
Martín, Del Valle, Saborit, Engel: Identification of Grb2 as a novel binding partner of the signaling lymphocytic activation molecule-associated protein binding receptor CD229. in Journal of immunology (Baltimore, Md. : 1950) 2005
Zeige alle 5 Referenzen für 2663193
Human Monoclonal LY9 Primary Antibody für FACS, IP - ABIN2479342
Antal: Global report on yaws and other endemic treponematoses. in The Southeast Asian journal of tropical medicine and public health 1987
Zeige alle 4 Referenzen für 2479342
Human Monoclonal LY9 Primary Antibody für FACS - ABIN119625
Abazov, Abbott, Abolins, Acharya, Adams, Adams, Agelou, Agram, Ahn, Ahsan, Alexeev, Alkhazov, Alton, Alverson, Alves, Anastasoaie, Andeen, Anderson, Andrieu, Anzelc, Arnoud, Arov, Askew, Asman, Jesus, Atramentov, Autermann, Avila, Ay, Badaud, Baden, Bagby: Measurement of the Bs(0) lifetime using semileptonic decays. in Physical review letters 2007
Zeige alle 3 Referenzen für 119625
Human Monoclonal LY9 Primary Antibody für FACS - ABIN119623
de la Fuente, Tovar, Villamor, Zapater, Pizcueta, Campo, Bosch, Engel: Molecular characterization and expression of a novel human leukocyte cell-surface marker homologous to mouse Ly-9. in Blood 2001
Zeige alle 2 Referenzen für 119623
Human Monoclonal LY9 Primary Antibody für FACS - ABIN4897608
Atanackovic, Panse, Hildebrandt, Jadczak, Kobold, Cao, Templin, Meyer, Reinhard, Bartels, Lajmi, Zander, Marx, Bokemeyer, Kröger: Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma. in Haematologica 2011
the results presented here suggest that the tumor suppressor potential of SLAMF3 occurs through activation of Retinoblastoma protein that represses PLK1 (zeige PLK1 Antikörper).
study showed CD229 is overexpressed on the malignant plasma cells of patients across all types of plasma cell dyscrasias including multiple myeloma; CD229 is also expressed on the surface of a fraction of cells carrying the phenotype of chemotherapy-resistant and myeloma-propagating cells within the patients' bone marrow
the Val602 variant of the non-synonymous single nucleotide polymorphism (SNP) rs509749 in the SLAM (zeige SLAMF1 Antikörper) family member CD229 (Ly9, SLAMF3) has a two-fold lower affinity compared with the SLE-associated Met602 variant for the small adaptor protein SAP (zeige APCS Antikörper)
CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance.
Results revealed that SLAMF3 plays a role during hepatitis C virus entry, likely by enhancing entry of viral particle within hepatocytes.
SLAMF3 is an inhibitor of hepatocellular carcinoma cell proliferation and tumor progression.
These results suggest a role for CD319 (zeige SLAMF7 Antikörper) and CD229 in the systemic lupus erythematosus disease process.
Data indicate that the dominance of the SLAMF3/SLAMF6 (zeige SLAMF6 Antikörper) pathway in inducing IL-17A (zeige IL17A Antikörper) production can be attributed to an increased nuclear abundance and recruitment of RORgammat to the IL17A (zeige IL17A Antikörper) promoter.
SLAMF3 and SLAMF6 (zeige SLAMF6 Antikörper) T cell surface expression and IL-17 (zeige IL17A Antikörper) levels significantly correlate with disease activity in systemic lupus erythematosus patients
CD229 is specifically over-expressed on myeloma cells including their clonogenic precursors and contributes to their malignant phenotype.
Ly9/CD229 cell surface receptor emerges as a uniquely important element for modulating innate T cell function, acting as an inhibitory molecule that regulates invariant natural killer (NK)T cell development and innate-like CD8 (zeige CD8A Antikörper) T cell expansion.
Data show that defective tolerance was observed only in Fcgr2b (zeige FCGR2B Antikörper)-deficient mice with autoimmune-type Slam (zeige SLAMF1 Antikörper) family genes, indicating that epistatic effects of both genes are involved.
mouse novel Ly9 (zeige SLAMF7 Antikörper) is a new member of the expanding CD150 (zeige SLAMF1 Antikörper) family of cell surface receptors
CD229 is a self-ligand, interacting through its N-terminal V-like domain which contains three amino acid residues critical for the homophilic binding interaction.
CD229 is a pan (zeige SUPT6H Antikörper)-lymphocyte marker and indicate that mAbs against CD229 are able to down-modulate T-cell activation.
LY9 belongs to the SLAM family of immunomodulatory receptors (see SLAMF1\; MIM 603492) and interacts with the adaptor molecule SAP (SH2D1A\; MIM 300490) (Graham et al., 2006
lymphocyte antigen 9
, T-lymphocyte surface antigen Ly-9
, T-lymphocyte surface antigen Ly-9-like
, t-lymphocyte surface antigen Ly-9-like
, SLAM family member 3
, cell surface molecule Ly-9
, signaling lymphocytic activation molecule 3